<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990519</url>
  </required_header>
  <id_info>
    <org_study_id>CR108637</org_study_id>
    <secondary_id>26366821RSS1001</secondary_id>
    <nct_id>NCT03990519</nct_id>
  </id_info>
  <brief_title>A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous
      (SC) dose of JNJ-26366821.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">February 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of JNJ-26366821</measure>
    <time_frame>Day 1: predose, 1, 4, 12 hours (hrs) postdose; Day 2: 24 and 36 hrs postdose; Day 3: 48 and 60 hrs postdose; Day 4: 72 hrs postdose; Day 5: 96 hrs; Day 6: 120 hrs postdose; Days 15 and 30</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of JNJ- 26366821.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve from Time 0 to Time of the Last Measurable Concentration AUC0-Last of JNJ-26366821</measure>
    <time_frame>Day 1: predose, 1, 4, 12 hours (hrs) postdose; Day 2: 24 and 36 hrs postdose; Day 3: 48 and 60 hrs postdose; Day 4: 72 hrs postdose; Day 5: 96 hrs; Day 6: 120 hrs postdose; Days 15 and 30</time_frame>
    <description>AUC 0-last is defined as area under the plasma concentration versus time curve from time 0 to time of the last measurable concentration of JNJ-26366821 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-Life (t1/2) of JNJ-26366821</measure>
    <time_frame>Day 1: predose, 1, 4, 12 hours (hrs) postdose; Day 2: 24 and 36 hrs postdose; Day 3: 48 and 60 hrs postdose; Day 4: 72 hrs postdose; Day 5: 96 hrs; Day 6: 120 hrs postdose; Days 15 and 30</time_frame>
    <description>T1/2 is define as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the JNJ-26366821 Concentration Versus Time Curve from Time 0 to Infinite Time (AUC[0-infinity]) of JNJ-26366821</measure>
    <time_frame>Day 1: predose, 1, 4, 12 hours (hrs) postdose; Day 2: 24 and 36 hrs postdose; Day 3: 48 and 60 hrs postdose; Day 4: 72 hrs postdose; Day 5: 96 hrs; Day 6: 120 hrs postdose; Days 15 and 30</time_frame>
    <description>AUC (0-infinity) is defined as area under the JNJ-26366821 concentration Versus time curve from Time 0 to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Observed Plasma Concentration (Tmax) of JNJ-26366821</measure>
    <time_frame>Day 1: predose, 1, 4, 12 hours (hrs) postdose; Day 2: 24 and 36 hrs postdose; Day 3: 48 and 60 hrs postdose; Day 4: 72 hrs postdose; Day 5: 96 hrs; Day 6: 120 hrs postdose; Days 15 and 30</time_frame>
    <description>Tmax is defined as time to reach the maximum observed plasma JNJ-26366821 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Platelet Count from Baseline at Each Dose and Time</measure>
    <time_frame>Baseline up to Day 30</time_frame>
    <description>Change from baseline in platelet count at each dose and time will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort1: JNJ-2636682/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of JNJ-26366821 or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: JNJ-26366821/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of JNJ-26366821 or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: JNJ-26366821/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-26366821</intervention_name>
    <description>Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).</description>
    <arm_group_label>Cohort 2: JNJ-26366821/Placebo</arm_group_label>
    <arm_group_label>Cohort 3: JNJ-26366821/Placebo</arm_group_label>
    <arm_group_label>Cohort1: JNJ-2636682/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive sodium chloride injection as placebo on Day 1.</description>
    <arm_group_label>Cohort 2: JNJ-26366821/Placebo</arm_group_label>
    <arm_group_label>Cohort 3: JNJ-26366821/Placebo</arm_group_label>
    <arm_group_label>Cohort1: JNJ-2636682/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overall good health, on the basis of full physical examination, medical history, vital
             signs, and 12-lead electrocardiogram (ECG) performed at screening

          -  Body weight 50 - 100 kilogram (kg), body mass index (BMI) 18 - 30 kilogram per meter
             square (kg/m^2), inclusive at screening

          -  Platelet count within range: 145 to 350*10^9/liter (L), inclusive at screening

          -  Hematologic values, coagulation profile, renal and liver function within normal range
             at screening or if out of range and considered not clinically significant by the
             investigator

          -  Non-smoker for at least the previous 3 months prior to screening and negative urine
             cotinine test at screening and admission

        Exclusion Criteria:

          -  History of any clinically significant medical illness or disorders the investigator
             considers should exclude the participant, including (but not limited to),
             neuromuscular, hematological disease, immune deficiency state, respiratory disease,
             hepatic or gastrointestinal disease, neurological or psychiatric disease,
             ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or
             dermatological disease

          -  Has a disease or disease treatment history associated with immune suppression or
             lymphopenia, these include but are not limited to bone marrow or organ
             transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes,
             splenectomy, functional asplenism, and chronic granulomatous disease

          -  Has a personal history of genetic or congenital prothrombotic condition or new
             conditions associated with thromboembolic events or bleeding disorders, including (but
             not limited to) myocardial infarction, cerebral vascular accident/stroke, deep vein
             thrombosis, pulmonary embolism, hemophilia, or menometrorrhagia

          -  Participants who had received hematopoietic growth factors within 3 months prior to
             study drug administration

          -  Donation of blood or blood components within 90 days prior to drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108637</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

